Discover
LRMR
Larimar Therapeutics, Inc.
2.67
2 x 2.95
2 x 5.29
bid
ask
-
0.03
1.11%
2 @ 07:40 PM
2.74 +0.07 (2.62%)
| Ytd | -29.92% | |
| 1y | -41.32% |
2.63
day range
2.74
2.67
52 week range
5.95
| Open | 2.68 | Prev Close | 2.70 | Low | 2.63 | High | 2.74 | Mkt Cap | 277.37M |
| Vol | 868.88K | Avg Vol | 1.27M | EPS | -1.99 | P/E | N/A | Forward P/E | -2.57 |
| Beta | 0.71 | Short Ratio | 5.19 | Inst. Own | 106.56% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 3.79 | 200-d Avg | 3.91 | 1yr Est | 20.41 |
| Income Statement | |||
| Operating Expenses | 34.35M | ||
| Research and Development Expense | 28.00M | ||
| Selling, General and Administrative Expense | 6.35M | ||
| Operating Income | -34.35M | ||
| Net Income | -32.78M | ||
| Net Income Common Stock | -32.78M | ||
| Net Income Common Stock (USD) | -32.78M | ||
| Consolidated Income | -32.78M | ||
| Earnings per Basic Share | 0.30 | ||
| Earnings per Basic Share (USD) | 0.30 | ||
| Earnings per Diluted Share | 0.30 | ||
| Earning Before Interest & Taxes (EBIT) | -32.78M | ||
| Earning Before Interest & Taxes (USD) | -32.78M | ||
| Weighted Average Shares | 103.88M | ||
| Weighted Average Shares Diluted | 103.88M | ||
| Balance Sheet | |||
| Cash and Equivalents | 93.14M | ||
| Cash and Equivalents (USD) | 93.14M | ||
| Investments | 63.58M | ||
| Investments Current | 63.58M | ||
| Current Assets | 160.67M | ||
| Property, Plant & Equipment Net | 3.69M | ||
| Total Assets | 165.30M | ||
| Debt Current | 1.20M | ||
| Total Debt | 4.96M | ||
| Current Liabilities | 34.17M | ||
| Debt Non-Current | 3.75M | ||
| Total Liabilities | 37.92M | ||
| Accumulated Retained Earnings (Deficit) | -497.23M | ||
| Accumulated Other Comprehensive Income | -12.00K | ||
| Shareholders Equity | 127.38M | ||
| Shareholders Equity (USD) | 127.38M | ||
| Assets Non-Current | 4.63M | ||
| Total Debt (USD) | 4.96M | ||
| Liabilities Non-Current | 3.75M | ||
| Trade and Non-Trade Payables | 7.60M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 50.00K | ||
| Net Cash Flow from Financing | -435.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -85.38M | ||
| Capital Expenditure | -130.00K | ||
| Issuance (Purchase) of Equity Shares | -435.00K | ||
| Net Cash Flow from Investing | -40.91M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -40.78M | ||
| Net Cash Flow from Operations | -44.03M | ||
| Share Based Compensation | 2.15M | ||